Kodiak Sciences (MEX:KOD) Total Long-Term Assets: MXN2,357.74 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KOD Kodiak Sciences Inc MEX:KOD
31 GF Score
Price MXN749.00
! 4 Warning Signs
View Full Analysis

What is Kodiak Sciences Total Long-Term Assets?

Kodiak Sciences MEX:KOD 31 Total Long-Term Assets is MXN2,357.74 Mil as of Mar. 2026. GuruFocus rates MEX:KOD with a GF Score™ of 31/100. The stock has 4 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Kodiak Sciences's Total Long-Term Assets for the quarter that ended in Mar. 2026 was MXN2,357.74 Mil.

Kodiak Sciences Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Kodiak Sciences's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kodiak Sciences Total Long-Term Assets Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,475.26 3,521.43 3,226.18 3,412.87 2,461.69

Kodiak Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,175.60 2,801.90 2,611.13 2,461.69 2,357.74
MEX:KOD
31GF Score
Kodiak Sciences Inc MEX:KOD
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kodiak Sciences Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of MXN2,357.74 Mil mean?
Kodiak Sciences (MEX:KOD) has a Total Long-Term Assets of MXN2,357.74 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Kodiak Sciences and its competitors.
Is Kodiak Sciences' Total Long-Term Assets too high?
Kodiak Sciences' current Total Long-Term Assets is MXN2,357.74 Mil. Overall, Kodiak Sciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' Total Long-Term Assets compare to ABCL and AGIO?
Kodiak Sciences' Total Long-Term Assets of MXN2,357.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Kodiak Sciences and its competitors. Kodiak Sciences's current Total Long-Term Assets is MXN2,357.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (MEX:KOD) has a current Total Long-Term Assets of MXN2,357.74 Mil. The current Total Long-Term Assets is MXN2,357.74 Mil. Kodiak Sciences' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Kodiak Sciences (MEX:KOD), the current Total Long-Term Assets is MXN2,357.74 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kodiak Sciences Business Description

Other Exchanges KOD:USAK27:Germany
Address 1250 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
31GF Score

Get the complete analysis for MEX:KOD

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN749.00
Price